Final answer:
The preferred treatment for Paroxysmal nocturnal hemoglobinuria is eculizumab, a terminal complement inhibitor that directly targets the disease's underlying mechanism.
Step-by-step explanation:
The treatment for Paroxysmal nocturnal hemoglobinuria (PNH) is eculizumab, which is a terminal complement inhibitor. This medication works by inhibiting the complement system that otherwise leads to the destruction of red blood cells in individuals with PNH.
While other treatment options such as blood transfusions, bone marrow transplants, and chemotherapy may be used in the management of PNH under certain circumstances, eculizumab specifically addresses the underlying mechanism of the disease and is therefore the preferred treatment in many cases.